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Schrauwen-Hinderling VB, Carpentier AC. Molecular imaging of postpran-
dial metabolism. J Appl Physiol 124: 504–511, 2018. First published May 11,
2017; doi:10.1152/japplphysiol.00212.2017.—Disordered postprandial metabolism
of energy substrates is one of the main defining features of prediabetes and
contributes to the development of several chronic diseases associated with obesity,
such as type 2 diabetes and cardiovascular diseases. Postprandial energy metabo-
lism has been studied using classical isotopic tracer approaches that are limited by
poor access to splanchnic metabolism and highly dynamic and complex exchanges
of energy substrates involving multiple organs and systems. Advances in noninva-
sive molecular imaging modalities, such as PET and MRI/magnetic resonance
spectroscopy (MRS), have recently allowed important advances in our understand-
ing of postprandial energy metabolism in humans. The present review describes
some of these recent advances, with particular focus on glucose and fatty acid
metabolism in the postprandial state, and discusses current gaps in knowledge and
new perspectives of application of PET and MRI/MRS for the investigation and
treatment of human metabolic diseases.
dietary fat; glucose; energy metabolism; positron emission tomography; magnetic
resonance imaging; magnetic resonance spectroscopy
INTRODUCTION
The postprandial state is defined as the period following
meal intake. It is characterized by net input of energy sub-
strates and other nutrients from the gastrointestinal track
into the splanchnic and systemic circulation. It is thus under
normal circumstances, an anabolic state also characterized
by complex neurohormonal responses and dynamic changes
in blood substrate appearance and disappearance rates. Its
duration is variable depending on the digestive rate of the
substrate and its downstream metabolism, for example,
ranging from 3 to 4 h (10) for glucose, in most instances, to
6 h for dietary fatty acid metabolism (30). Because most
individuals eat three or more meals per day, it follows that
humans are spending most of the time in the postprandial
state, at least with regards to dietary fat metabolism. How-
ever, physiological measurements are most often performed
in the fasted state to ensure standardization, when metabolic
abnormalities are often not apparent. Metabolic disorders
often become evident only after a metabolic challenge, for
example, after a meal.
By definition, impaired glucose tolerance is an exaggerated
postprandial blood glucose excursion. It is a main risk factor
for the development of type 2 diabetes and a major defining
feature of prediabetes (1). Impaired glucose tolerance and type
2 diabetes are also associated with other disordered postpran-
dial responses of energy substrate metabolism, such as plasma
nonesterified fatty acids (NEFAs) and triglycerides (7, 44),
amino acids (2), and ketone bodies and lactate (15). As such,
the natural history spectrum, from prediabetes to overt type 2
diabetes, displays a varying degree of metabolic inflexibility of
different energy substrates from the fasting to the postprandial
state, leading to disordered postprandial metabolic responses,
including that of fatty acids, amino acids, and glucose itself,
demonstrated to play significant roles in the development of
type 2 diabetes and many of its end-organ complications,
including atherosclerosis, heart failure, and kidney dysfunction
(6, 18, 38, 55, 57).
Isotopic tracer studies, using the classical blood or plasma
dilution techniques and various modeling methods, have pro-
vided important advances in knowledge of postprandial glu-
cose, NEFA, dietary fatty acid, and amino acid metabolism in
physiological and pathophysiological conditions. For example,
simultaneous intravenous and prandial administration of
tracers have quantified the contribution of endogenous vs.
exogenous substrate appearance to a postprandial metabo-
lism (37, 43). Breath sampling with determination of isoto-
pic labeling of CO2 has allowed quantification of dietary and
endogenous substrate whole-body oxidation rates (43, 44).
Administration of fatty acid tracers with arteriovenous sam-
pling and/or adipose tissue biopsies has also provided in-
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sight into dietary fatty acid adipose tissue storage (7, 39, 40,
54). However, the study of the postprandial state has been
very challenging, even using these state-of-the-art ap-
proaches, given their incapacity to monitor directly the
digestive and absorptive metabolism of substrate, their lim-
ited access to the splanchnic circulation, the incapacity to
monitor many organs simultaneously, and severely limited
time resolution and repeatability of most of these ap-
proaches. Postprandial energy substrate metabolism is dy-
namic (i.e., highly time dependent), has a variable latent
period in usually inaccessible compartments (i.e., gastroin-
testinal tract and splanchnic circulation), and often involves
multiple organs that contribute to the disappearance but also
in some instances, to recirculation of these substrates (i.e.,
liver for glucose and adipose tissues for dietary fatty acids;
see below).
Major advances have been made in noninvasive molecular
imaging methods over the past decades, allowing for the study
of glucose, fatty acid, and amino acid metabolism. With the
allowance of noninvasive access to virtually all organ-system
metabolisms with higher time resolution and repeatability,
these newer tools circumvent many of the limitations of clas-
sical tracer methods. Two of these imaging modalities have
been particularly useful for the study of energy substrate
metabolism in humans: 1) PET and 2) MRS/magnetic reso-
nance spectroscopy (MRS; Fig. 1).
PET is based on detection of the two simultaneous gamma
photons, emitted almost in the opposite direction, when a
positron meets an electron and disintegrates. This unique
property of positron-emitting radionuclides (carbon-11 or 11C,
nitrogen-13 or 13N, oxygen-15 or 15O, fluorine-18 or 18F,
gallium-68 or 68Ga, zirconium-89 or 89Zi, rubidium-82 or
82Ru, and others) potentially allows for accurate localization of
the disintegration event along a straight line (or line of re-
sponse) using two gamma detectors aligned around the subject,
provided that the resolving time of the detectors is small
enough (typically 500 ps). This allows for more precise
three-dimensional reconstruction of coincident gamma photon
detection events and the highest sensitivity of PET reaching the
picomolar range compared with other radionuclide imaging
modalities and MRS (in the millimolar range) (41). This
exquisite molecular sensitivity of PET permits the use of very
small doses of tracers having very highly specific activity (i.e.,
radioactivity divided by the mass of tracer). This makes PET
an optimal tracer technique in most instances (and certainly in
all instances for the study of energetic substrates, such as
glucose and fatty acids, found in large concentrations in cir-
culation), as the tracer-to-tracee ratio is minimized (an assump-
tion of the tracer-dilution model). Although PET is an excellent
method to track exogenous tracers, the strength of MRS is to
detect and quantify endogenous metabolites and monitor the
physiological response upon a meal challenge. The high sen-
sitivity of PET makes it possible to use molecules in minute
PET-tracer doses [e.g., 18-fluorodeoxyglucose (18FDG) and
18-fluorothiaheptadecanoic acid (18FTHA)], which would per-
turb the metabolic processes under study and have harmful
metabolic effects at large doses (18FDG competitively blocks
glycolysis, and 18FTHA competitively blocks fatty acid me-
tabolism). Combined with the relatively large array of posi-
tron-emitting radionuclides, this allows for theoretically unlim-
ited versatility of PET tracers with different properties to study
any biological process. For example, the glucose metabolism
can be studied using 11C-glucose, which is metabolized exactly
as endogenous glucose (i.e., tissue uptake and cellular meta-
bolic pathways are all at tracee rates), or using 18FDG, which
is taken up by tissues at approximately the same rate as glucose
but not metabolized beyond the first phosphorylation step (i.e.,
mediated by glucokinase or hexokinase) in cells (52, 56). Thus
11C-glucose is ideal to study the glucose oxidative and non-
oxidative metabolism, whereas 18FDG is ideal to measure
integrated uptake of glucose in tissues over time, improving the
detection and imaging of some organs or structures, such as
brown adipose tissues (8, 12, 50, 53, 62, 67).
Two acquisition modalities are used for PET metabolic
imaging: 1) whole body (“static scanning”) and 2) dynamic
acquisition (Fig. 2). The first is the most commonly used
acquisition modality and serves for anatomical detection of
structures (i.e., tumors) or the determination of relative uptake
(biodistribution or partitioning, usually quantified as “standard
uptake value”) of the PET tracer. Static scanning is typically
used with tracers displaying delayed tissue metabolic clear-
ance, such as 18FDG or 18FTHA, allowing the comparison of
the cumulative tracer uptake among different tissues
throughout the whole body. It may give precise measure-
ment of relative integrated uptake of the tracee among
tissues but cannot precisely determine quantitative fluxes in
and out of the tissues. Dynamic scanning, on the other hand,
directly measures fluxes in and out of tissues. It is, however,
more fastidious to perform, requiring relatively long acqui-
sition scans targeted to a limited anatomic area (i.e., the field
of view of the scanner, typically 24 cm along the axis of
the body); determination of a blood tracer and metabolite
concentrations; and modelization of the data using linear-
ization, compartmental modeling, or spectral analysis (11,
51, 60, 61).
Fig. 1. Complementary strengths of MRI/magnetic resonance spectroscopy
(MRS) and PET/computed tomography (CT) for postprandial metabolic
imaging.
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The major drawbacks of PET are its high cost; the need
for synthesis of the PET tracers on site in most instances,
given the very short radioactive half-life of most positron-
emitting radionuclides (a few minutes to a few hours); and
radioactivity exposure of the participants. The latter se-
verely limits the capacity to repeat measurements over time
using this approach. All positron-emitting radionuclides
emit the gamma photon of the same energy level, limiting
the capacity to perform simultaneous acquisitions using two
or more PET tracers. Finally, the relatively low PET spatial
resolution results in partial volume effects with signal spill-
over of surrounding structures, making impossible some
measures (e.g., epicardial adipose tissue fatty acid uptake
because of very high relative myocardial uptake) and ren-
dering mathematical corrections of the data essential for
quantification purposes (11).
The potential of MRS as a complementary method to PET is
excellent, as it can accurately determine endogenous concen-
trations of metabolites and monitor their response upon con-
sumption of a meal. MRS makes use of a property that certain
nuclei possess, which is termed “spin” and which results in a
measurable net magnetization when exposed to the strong
magnetic field in an MRI scanner. Several nuclei have this spin
characteristic. The most interesting nuclei for metabolic re-
search are hydrogen (1H), phosphorous (31P), and carbon (13C).
Therefore, metabolites that contain hydrogen, phosphorous, or
carbon atoms can be detected if they are freely mobile and
present in millimolar concentrations. The resonance frequency
of nuclei can shift depending on the presence of surrounding
chemical liaisons, allowing for the identification and quantifi-
cation of chemical groups using the area under the peak of the
spectrum, which is directly proportional to the concentration.
The easiest way for quantification is the use of an internal
reference with known concentration (for example, water or
creatine). For such relative quantification, the ratio of metab-
olite/reference suffices to deduce tissue concentrations in milli-
molars per kilogram. For protons, the most abundant metabo-
lites in human tissue are water and lipids, and an important
application of 1H-MRS in metabolic research is the quantifi-
cation of muscle and liver fat content (intramyocellular lipids
and intrahepatic lipids; Fig. 3). In addition, creatine and cho-
line can typically be detected (e.g., in muscle tissue), and when
spectral editing is performed, many more metabolites, such
as acetylcarnitine or lactate, can be detected. In fact, future
development of new MR editing sequences will facilitate the
detection and quantification of yet-unobservable metabo-
lites. The field of 31P-MRS mainly focuses on the investi-
gation of energy metabolism, as high-energy metabolites,
such as ATP and creatine phosphate, can be quantified.
13C-MRS has been mostly applied to determine glycogen
concentrations; however, applications of 13C-MRS can po-
tentially be much broader. Most carbon atoms have a mass
number of 12, whereas only carbon nuclei with a mass
number of 13 possess spin, and therefore, only these yield
an MRS signal. The natural abundance of 13C is only 1.1%,
and together with the low sensitivity of 13C-MRS, this is
severely limiting signal intensity. However, the low natural
abundance of 13C also has advantages, as 13C-labeled sub-
strates can be used as stable (nonradioactive) tracers in











Fig. 2. Whole-body PET (top left) coupled to
low-dose computed tomography (CT; top mid-
dle) with merged PET-CT images (top right)
after oral administration of 18-fluorothiahep-
tadecanoic acid (18FTHA) in a healthy subject,
with examples of multicompartmental model-
ing of PET dynamic acquisition in list mode
after intravenous injection of 11C-palmitate to
determine cardiac (bottom left) and liver (bot-
tom right) oxidative and nonoxidative nones-
terified fatty acid metabolism. PET/CT oral
18FTHA data are from a participant of a pre-
viously published study (28). 11C-Palmitate
dynamic PET data are from an unpublished
study, using multicompartmental models from
de Jong et al. (13) for the heart and Iozzo et al.
(20) for the liver.
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investigating metabolism (see MOLECULAR IMAGING OF POST-
PRANDIAL FATTY ACID METABOLISM).
MOLECULAR IMAGING OF POSTPRANDIAL GLUCOSE
METABOLISM
Postprandial glucose metabolism, including the contribution
of exogenous vs. endogenous glucose appearance to systemic
glucose metabolism, has been very well studied using conven-
tional tracers (10, 37). Molecular imaging approaches using
PET have been used far less to determine the organ-specific
glucose metabolism during the postprandial state. Postprandial
metabolic glucose imaging by PET is complicated by at least
three important factors: 1) dynamic changes in insulin and
incretin hormones; 2) changes in circulating fluxes of fatty
acids that metabolically compete with glucose uptake and
metabolism, at least in some organs; and 3) postprandial
increase in circulating glucose level.
Insulin can increase organ-specific glucose uptake and me-
tabolism directly through stimulation of cell membrane glu-
cose transport and downstream metabolism and indirectly
by modification of systemic metabolic rates of other sub-
strates, especially through reduction of circulating NEFA.
Insulin is known to increase glucose uptake in the heart (17,
27), skeletal muscles (46), liver (21, 22), brain (19), and
adipose tissue depots (23, 63), including brown adipose tissues
(47). Organ-specific, insulin-stimulated glucose uptake is,
however, strongly determined by insulin-mediated suppression
of plasma NEFA (26, 45). Glucagon-like peptide 1 has also
been shown to reduce blood-brain glucose transport using
18FDG PET (33).
18FDG PET has been used for cardiac, brain, and brown
adipose tissue imaging during the postprandial state. For ex-
ample, the postprandial biodistribution of circulating glucose
between brown and white adipose tissues and lean organs using
18FDG PET has been described and compared with that during
acute cold exposure [which activates brown adipose tissue
thermogenesis (49)] in healthy men, showing lower brown
adipose tissue and higher skeletal muscle glucose uptake in the
cold vs. postprandial state (64). However, when compared with
the fasting state, brown adipose tissue glucose uptake appears
to be lower in the postprandial state (66). This likely results
from metabolic competition from dietary fatty acids, as we
recently showed that these substrates can be directly used by
brown adipose tissues in humans (5). Meals are, on occasion,
used to modify organ glucose uptake to the benefit of 18FDG
PET clinical investigations. For example, high-fat meals are
frequently used to suppress physiological cardiac glucose up-
take (through metabolic competition from dietary fatty acids;
see MOLECULAR IMAGING OF POSTPRANDIAL FATTY ACID METABO-
LISM) in preparation for 18FDG PET examination for myocar-
dial inflammation or infection or to detect arterial inflammation
(14, 48).
Some aspects of postprandial glucose metabolism can also
be investigated with MRS. For example, glycogen concentra-
tions can be determined in the liver and in skeletal muscle
before and after meals, and therefore, net glycogen storage
after a meal can be determined. With the use of this method, it
has been shown that glycogen concentration in muscle is
increased by 17% in healthy volunteers after a series of three
meals, whereas glycogen concentration in patients with type 2
diabetes mellitus remains unchanged, illustrating a disturbed
glycogen storage in muscle in the diabetic state (36). In the
liver, glycogen concentrations were also increased after the
meals, but here, this postprandial response is not blunted in
type 2 diabetes (36). Net glycogen storage can also be deter-
mined after a single meal, and peak glycogen concentrations in
the liver were found at 3–4 h after a meal (3). Furthermore, it
is reported that a meal with a high glycemic index leads to
more pronounced postprandial glycogen storage when com-
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Fig. 3. Axial MRI of the liver (left) with a
phosphorus-31 (31P) magnetic resonance (MR)
spectrum showing high-energy phosphate me-
tabolites (top right), a proton (1H) MR spec-
trum showing liver fat content (middle right),
and a proton-observed carbon-13 (13C)-edited
MR spectrum to determine deposition of 13C-
labeled dietary fatty acids in the liver (lower
right). PDE, phosphodiester; pi, inorganic
phosphate; PME, phosphomonoester; ppm,
parts per million.
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MOLECULAR IMAGING OF POSTPRANDIAL FATTY ACID
METABOLISM
Hepatic fat content can be monitored by 1H-MRS (Fig. 3),
and it was shown that 2–3 h after a high-fat, high-energetic
meal, hepatic fat content is increased by 13–20% in healthy,
lean subjects, indicating net hepatic fat storage after a meal (16,
35). Hepatic fat content was also shown to remain elevated at
5 h after the meal (35). On the other hand, lipid content in
skeletal muscle remained unchanged in the postprandial state.
Whereas 1H-MRS is broadly applied for monitoring total lipid
content in several organs, no information of the source of fat is
gained, as endogenous and exogenous fatty acid sources cannot
be differentiated. In that respect, 13C-MRS offers unique pos-
sibilities, as due to the low background of the 13C signal
(natural abundance of 13C is 1.1%), the 13C-labeled substrate
can be used as tracers, the signal of which can then be followed
in vivo. In that way, the substrate can be tracked, and uptake
and turnover can be monitored. For example, 13C-labeled fatty
acids were added to a meal, and the 13C lipid signal could be
monitored in the liver (34). However, the big challenge in such
experiments is the low sensitivity of 13C-MRS and possible
contamination of the measured signal from the 13C lipid signal
from adipose tissues. Therefore, to realize such experiments,
specialized MRS sequence development was necessary to ob-
tain good localization of the 13C signal and a sufficient signal-
to-noise ratio to monitor the 13C lipid signal in time. This was
possible by implementation of an indirect method to detect
13C-labeled lipids by selectively retaining the 1H signal of
13C-coupled spins (Fig. 3). This strategy makes use of the
higher sensitivity of 1H-MRS compared with 13C, to be able to
pick up the small differences in the 13C signal. With the use of
this method, it was shown that fatty acids, originating from a
mixed liquid meal, indeed accumulate in the liver in the first
3–5 h after a meal and that this is the case in lean as well as in
overweight to obese subjects (34).
A novel PET/computed tomography method has been intro-
duced recently for the quantification of organ-specific dietary
fatty acid uptake and partitioning in most organs of the human
body using oral administration of 18FTHA (Fig. 2) (30). Orally
administered 18FTHA reaches the circulation almost exclu-
sively in chylomicron triglycerides and is then taken up by
most tissues and partly recycled in circulation in the form of
NEFA by adipose tissues and VLDL triglycerides by the liver,
as expected for a long-chain dietary fatty acid (30). 18FTHA is
taken up in tissues at a similar rate as palmitate (25, 58) and
is trapped in oxidative and nonoxidative cellular pathways (9),
therefore allowing the progressive accumulation of this tracer
to determine organ-specific dietary fatty acid partitioning. The
PET oral 18FTHA method has shown peak dietary fatty acid
uptake between 3 and 5 h after a meal in most organs (30),
including the liver—a finding that fits well with those from the
13C-MRS method described in the preceding paragraph (34).
This novel technique has also demonstrated reduced dietary
fatty acid partitioning per volume of central adipose tissues in
prediabetes (28, 31)—a finding that is in line with those
demonstrated using classical tracer methods with biopsies or
arteriovenous gradient (7, 24, 39, 65). In addition, PET imag-
ing allowed the simultaneous demonstration of normal skeletal
muscle and liver but increased dietary fatty acid partitioning in
the heart of prediabetic subjects (28, 31). Increased cardiac
partitioning of dietary fatty acids in prediabetes is associated
with reduced left ventricular function (31) and insulin resis-
tance (42) and occurs via increased chylomicron transport in
men and via increased adipose tissue spillover of NEFA in
women (28). Excessive cardiac dietary fatty acid uptake and
partitioning and subclinical reduction in left ventricular func-
tion are corrected by weight loss for over 1 yr following
lifestyle modification (32) but not after 7 days of a hypocaloric,
low-fat diet (43).
The recent application of this technique during acute cold
exposure in healthy subjects, before and after prolonged cold
acclimation, has demonstrated, for the first time, brown adi-
pose tissue dietary fatty acid use in humans (5). In the later
study, it was shown that brown adipose tissue can use only
~1% of dietary fatty acids even after prolonged cold acclima-
tion that enhances the brown adipose tissue oxidative metab-
olism, demonstrating the limited role of this tissue for dietary
fatty acid clearance in humans.
MOLECULAR IMAGING OF POSTPRANDIAL TISSUE
OXIDATIVE METABOLISM
As mentioned above, next to 1H- and 13C-MRS, 31P-MRS is
also possible (Fig. 3), enabling the quantification of high-
energy metabolites, such as nucleoside triphosphate (ATP and
GTP). With the use of this method, it was shown that a
high-fat, high-energetic meal tends to increase mean nucleo-
side triphosphate concentrations in healthy subjects by 6%,
suggesting an increase of hepatic ATP energy reserves upon
meal consumption. The physiological implications of these
findings are not completely clear yet, although evidently,
sufficient ATP availability is a prerequisite for many postpran-
dial processes, including glycogen synthesis. Interestingly,
ATP concentrations decreased in response to fructose ingestion
in the liver during the first 50 min after ingestion (3), and the
time until ATP reserves were depleted was related to body
mass index, with the leaner subjects showing a slower decrease
in ATP (4). The underlying mechanism of this fructose-in-
duced ATP decrease in the liver remains to be elucidated,
although the phenomenon may be indicative of the ATP use by
fructose-induced stimulation of neoglucogenesis and de novo
lipogenesis (59). 11C-Acetate PET has also been used in the
postprandial state, demonstrating increased cardiac but normal
liver oxidative metabolism in subjects with prediabetes (31).
The postprandial skeletal muscle oxidative metabolism was
demonstrated similar to healthy subjects in patients with type 2
diabetes by 11C-acetate PET (29). The later study also showed
that reduction of muscle blood flow in type 2 diabetes is
associated with reduced muscle fractional extraction of plasma
NEFA determined by intravenous injection of 18FTHA with
PET. Interestingly, net postprandial muscle NEFA uptake was
nevertheless normal in these patients, because higher circulat-
ing NEFA compensates for the reduction in muscle NEFA
fractional extraction (29).
FUTURE PERSPECTIVES
PET and MRI/MRS now offer extended capacities to inves-
tigate the postprandial metabolism in physiological and path-
ological conditions. These two modalities have obvious com-
plementary strengths. PET has unsurpassed versatility and
sensitivity for the quantification of tissue in- and outflow of
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energy substrates, whereas MRI/MRS has the outstanding
capacity for noninvasive quantification of tissue metabolic
pools and composition. The recent advances in hybrid PET/
MRI, which offer the capacity for simultaneous PET and MRS
measures, will open novel windows on the intricate, multiorgan
metabolic abnormalities at play in the development of chronic
diseases, such as diabetes and cardiovascular disorders.
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